摘要
目的探讨前列腺癌患者血清前列腺特异抗原(PSA)、雄激素受体(AR)表达、Gleason评分和临床分期之间的相关性。方法回顾性分析我院55例前列腺癌患者的临床、病理和免疫组化资料。结果TPSA、FPSA值与Gleason评分、临床分期呈正相关,TPSA、FPSA、AR表达强度以及Gleason评分均与临床分期呈正相关(相关系数分别为:0.419,0.385,0.376,0.514),其中Gleason评分与临床分期的相关性最高。随着TPSA值的升高,对晚期Pca的判断价值明显增大,以TPSA≥30ng/ml为标准判断晚期Pca的准确性较高。结论TPSA、FPSA值、AR表达强度以及Gleason评分值与临床分期有正相关关系,它们可以作为进行临床分期时需综合考虑的因素;TPSA≥30ng/ml可以作为判断晚期Pca有价值的标准。
Objective To investigate the correlation among the serum TPSA, FPSA, androgen receptor （AR） expression, Gleason score and clinical stages of prostatic cancer. Methods The clinical, pathological and immunohistochemieal data of 55 cases patients with prostatic cancer were studied. Results A positive correlation was demonstrated between TPSA, FPSA level and Gleason score, clinical stages （correlation coefficients were as follows：0.419,0.385,0.376,0.514）. The correlation between Gleason score and clinical staging were the most significant. Advanced prostatic cancer was significantly elevated with TPSA levels increased. TPSA≥ 30 ng/ml was a better standard in determining advanced prostatic cancer. Conclusion There is positive correlation between TPSA, FPSA level, AR expression, Gleason score and clinical stages. They were the useful factors to define the clinical stages. TPSA≥30 ng/ml was a better standard in determining advanced prostatic cancer.
出处
《岭南现代临床外科》
2009年第3期186-188,191,共4页
Lingnan Modern Clinics in Surgery
